Synthesis and Biological Activities of a 3′-Azido Analogue of Doxorubicin Against Drug-Resistant Cancer Cells by Yu, Shuwen et al.
Int. J. Mol. Sci. 2012, 13, 3671-3684; doi:10.3390/ijms13033671 
 





Synthesis and Biological Activities of a 3'-Azido Analogue of 
Doxorubicin Against Drug-Resistant Cancer Cells 
Shuwen Yu 
1,2,3, Guisheng Zhang 
4, Wenpeng Zhang 
2, Huanhua Luo 
3, Liyun Qiu 
3,  
Qingfeng Liu 
4, Duxin Sun 
5, Peng-George Wang 
2,6,* and Fengshan Wang 
1,*
 
1  School of Pharmaceutical Sciences, Shandong University, Jinan 250012, China;   
E-Mail: yushuwen@sdu.edu.cn 
2  Department of Chemistry and Biochemistry, The Ohio State University, Ohio 43210, USA;   
E-Mail: zhangwenpeng@gmail.com 
3  Jinan Central Hospital Affiliated to Shandong University, Jinan 250011, China;   
E-Mails: zxyylhh@163.com (H.L.); qiuliyun7777@163.com (L.Q.) 
4  College of Chemistry and Environmental Sciences, Henan Normal University, Xinxiang 453002, 
China; E-Mails: zgs@henannu.edu.cn (G.Z.); greendiv@yahoo.com.cn (Q.L.) 
5  College of Pharmacy, The University of Michigan, Michigan 48109, USA;  
E-Mail: duxins@umich.edu 
6  College of Pharmacy, Nan Kai University, Tianjin 300071, China 
*  Authors to whom correspondence should be addressed; E-Mails: pwang@nankai.edu.cn (P.-G.W.); 
fswang@sdu.edu.cn (F.W.); Tel.: +86-22-2350-6290 (P.-G.W.); +86-531-8838-2589 (F.W.);   
Fax: +86-22-2350-7760 (P.-G.W.); +86-531-8838-2548 (F.W.). 
Received: 13 February 2012; in revised form: 7 March 2012 / Accepted: 13 March 2012 / 
Published: 19 March 2012 
 
Abstract:  Doxorubicin (DOX), an anthracycline antibiotic, is one of the most active 
anticancer chemotherapeutic agents. The clinical use of DOX, however, is limited by the 
dose-dependant P-glycoprotein (P-gp)-mediated resistance. Herein, a 3′-azido analogue of 
DOX (ADOX) was prepared from daunorubicin (DNR). ADOX exhibited potent antitumor 
activities in drug-sensitive (MCF-7 and K562) and drug-resistant cell lines (MCF-7/DNR, 
K562/DOX), respectively. The drug resistance index (DRI) values of ADOX were much 
lower than that of DOX. The cytotoxicity experiments of ADOX or DOX against 
K562/DOX, with or without P-gp inhibitor, indicated that ADOX circumvents resistance by 
abolishing the P-gp recognition. This conclusion was further supported by drug influx/efflux 
flow cytometry experiments, as well as by molecular docking of ADOX to P-gp. In vivo 
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animal tests, ADOX exhibited higher activity and less toxicity than DOX. The current data 
warranted ADOX for additional pre-clinical evaluations for new drug development. 
Keywords: anthracycline; Azido; multidrug resistance; ADOX; P-gp  
 
1. Introduction 
The anthracycline family of antibiotics, such as daunorubicin (DNR) and doxorubicin (DOX) 
(Figure 1), are among the most effective anticancer drugs used, either as single agents or in 
combination in chemotherapy. Anthracyclines are widely used in cancer chemotherapy, but the clinical 
uses are limited by two major problems: multidrug resistance (MDR) [1,2] and cardiotoxicity. MDR is 
a simultaneous development of resistance to a variety of anticancer drugs in cancer therapy. Many 
factors are involved in MDR. One of the mechanisms for drug resistance of anthracyclines is mediated 
by an ABC transporter protein P-glycoprotein (P-gp) because P-gp is overexpressed in many 
drug-resistant cancer cells [1–8]. P-gp actively exports many anticancer drugs (including 
anthracyclines) to confer drug resistance. After drugs are diffused into cells, they bind to intracellular 
domains of P-gp and trigger ATP binding to the nucleoside binding domain (NBD) and the hydrolysis 
of ATP. The energy from the ATP hydrolysis exports the drugs out of cells. The mechanism of P-gp 
transport has been well-characterized; however, many attempts to circumvent resistance by P-gp 
inhibitors have not been successful. The second limitation for the clinical use of anthracyclines is the 
peculiar, and often irreversible, cardiac toxicity. Cardiac toxicity of anthracyclines is represented by 
the development of cardiomyopathy and ultimately congestive heart failure. The mechanisms of 
anthracycline-induced cardiac toxicity are rather complex and multi-factorial. In this paper, our work 
is based on solving the first problem, drug resistance. 
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The 3′-NH2 group of anthracyclines has been reported to be critical for P-gp binding [9]. Previously, 
we proved that P-gp mediated MDR of DNR could be successfully overcome via the chemical 
conversion of DNR into 3-azido daunorubicin (ADNR)  [10,11]. DOX and DNR share the same 
molecular skeleton except for the side chain at C-14, where DNR carries no functional group and DOX 
bears a hydroxyl group. Such a small structural difference makes DOX much more potent than DNR, 
and DOX has broader anticancer activity against leukemia, lymphomas, and various solid tumors Int. J. Mol. Sci. 2012, 13                 
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including breast, small cell lung, cervical, head, and neck cancers. Thereupon, the strategy to design 
derivatives of DOX that are not recognized by P-gp is warranted. It is of great interest for us to 
synthesize the 3′-azido analogue of DOX (ADOX), and to investigate the antitumor activity of it. 
2. Results and Discussion 
2.1. Molecular Modeling 
Before the synthesis of ADOX, we looked at the interactions of DOX and ADOX with human P-gp 
protein by homology modeling on the basis of X-ray structure of mouse P-gp (PDB entry:3G60) 
(Figure 2A,B) [12]. In brief, DOX is able to form hydrophobic and/or π-stacking interactions with 
residues Phe 71, Ile 336, Phe 339, Phe 728, Leu 971, Phe 974 and Val 978 (Figure 2C). Moreover, 
DOX can contact Tyr 303 by providing two hydrogen bonds. These favorable interactions allowed the 
docked complex a low binding free energy of −12.70 kcal/mol. In contrast, ADOX bound to P-gp 
mainly depended on hydrophobic and/or π-stacking interactions with residues Ile 336, Phe 728, Leu 971, 
Phe 974 and Val 978 (Figure 2D), which granted the proposed complex an unfavorable binding free 
energy of 1.31 kcal/mol, implying that ADOX was a poor substrate for P-gp. This result may be 
caused by the bulky azido substitution that would push ADOX away from the active cavity. This 
modeling result and the broad anticancer spectrum of DOX promoted us to synthesize ADOX for  
in vitro and in vivo antitumor tests. 
Figure 2. Molecular Docking of DOX and ADOX to P-gp. (A) Ribbon diagram of P-gp 
(PDB entry:3G60) complexed with compounds DOX (yellow sticks) and ADOX (green 
sticks); (B) The proposed docking conformation of compounds DOX (yellow sticks) and 
ADOX (green sticks) around docking spheres (white spheres) in P-gp; (C) Proposed 
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2.2. Synthesis of ADOX 
ADOX was prepared from DNR by employing the glycosylation reaction of 
14-actyoxydoxorubicinone (6) with an azido sugar (3) which was prepared from the hydrolysis of 
DNR hydrochloride (Scheme 1). The synthesis of aglycon 6 and glycosyl donor 3 started with the 
hydrolysis of DNR hydrochloride with dilute HCl at 90 °C for 1 h. Aqueous acidic hydrolysis of 
hydrochloride of DNR with 0.2 M hydrochloric acid at 90 °C gave daunorubicinone (4) and 
hydrochloride of daunosamine (1) in 90% yield [13]. Compound 4 was obtained after filtration as a red 
powder. The filtrate was evaporated to dryness to give the aminosugar 1  containing a little of 
daunorubicinone 4. To get a pure 1, we tried to purify the crude product by recrystallization with 
ethanol. However, a glycoside, ethyl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexoside was obtained in 83% 
yield instead of hydrochloride of daunosamine. Finally, the pure aminosugar was obtained via a 
thorough washing of the filtrate with methylene dichloride before the evaporation. The azido sugar 2 
could be prepared readily from 1 according to C.-H. Wong’s method [14]. Subsequent treatment of 2 
with thiophenol in the presence of boron trifluoride diethyl etherate gave the α-anomer of 
thioglycoside 3 in overall yield of 65% from aminosugar 1. The aglycon 6 was directly prepared from 
its DNR counterpart 4 based on reported procedures [15]. The conversion was accomplished by 
bromination of 4 with 30% bromine/chloroform in methanol/dioxane followed by the nucleophilic 
displacement type esterification of 14-bromodaunorubicinone 5 with sodium acetate in acetone. In the 
literature [15], the yields of these two steps are 92% and 96%, respectively. However, we found the 
bromination step was in low yield (< 40%) after repeating the procedure several times and the bromide 
5 is unstable. We obtained the aglycon 6 in overall yield of 36% from daunorubicinone 4. In this 
procedure, the 14-hydroxyl group of doxorubicinone was selectively acetylated which allowed the 
compound directly use in the subsequent glycosylation. Acetyl group was used for protecting the 
hydroxyl functions present in glycosyl donor 3 and aglycon 6, because they were cleavable under  
0.1 M NaOH in THF, which allowed the acid and strong base sensitive aglycon moiety in the 
anthracycline molecule not to be affected in the final deprotection. 
Previous research has indicated that the linkage between the sugar moiety and the aglycon is very 
important. Only the α-linked anthracycline analogues are biologically active. Therefore, the azido 
sugar has to be introduced stereoselectively in α-linkage. For 2-deoxy sugars, without the 
stereodirecting ability of 2-substituents, direct and efficient α-selective glycosylations are difficult to 
realize [16,17]. Hirama and co-workers reported a direct and efficient α-selective glycosylation 
protocol for the kedarcidin sugar and L-mycarose using AgPF6 as a remarkable activator of 
2-deoxythioglycosides [18]. Recently, we developed a concise promoter system AgPF6/TTBP to 
activate 2-deoxythioglycosides for synthesis of α-linked glycosides [13,19]. Therefore, in our 
glycoaylation shown in Scheme 1, glycosyl sulfide was used as glycosyl donor for the α-glycosylation 
of the azido sugar. Initially, we tried to use the promoter system AgPF6/TTBP in the glycosylation. 
However, we found the promoter system did not work well for the glycosylation of the glycosyl 
acceptor 6 with donor 3. Though the condensation exclusively formed the α-product, the yield was 
very low (< 8% yield). On scrutinizing various promoter systems for activating glycosyl sulfides, 
finally we were contended with result obtained by NIS/TfOH system. The mixture of aglycon 6 and 
sugar donor 3, in the presence of NIS and molecular sieves (4 Å, < 5 microns, freshly activated), was Int. J. Mol. Sci. 2012, 13                 
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treated for 0.5 h with TfOH at 0 °C to give the glycosylated product 7 in 64% yield (Scheme 1). The 
1H NMR data indicated that the desired α-linkage was formed predominantly (α:β > 10:1). The  
1H NMR of 7 showed that the value of J1′,2′ (2.4 Hz) was in accord with α-anomer. Mild deprotection 
of 7 with 0.1 M NaOH in THF afforded the final product ADOX in 70% yield. The NMR spectra of 
the deprotective product were identical to that of the compound ADOX obtained in the procedure 
shown in Scheme 1. 
Scheme 1. Synthesis of ADOX from DNR. (a) 0.2 M HCl, 90 °C, 1 h; (b) K2CO3, CuSO4, 
TfN3, solution; then Ac2O/pyridine; (c) PhSH, BF3·Et2O, CH2Cl2, 0 °C, 2 h;   
(d) Trimethylorthoformate, MeOH/1,4-dioxane, rt, 20 min; then Br2/CHCl3, rt, 6 h;  
(e) NaOAc/acetone, reflux, 6 h; (f) NIS, TfOH; (g) 0.1 M NaOH/THF, 0 °C. 
 
2.3. In Vitro Biological Tests of ADOX 
To test if the new anthracycline analogue ADOX could overcome drug resistance, MTS assays were 
performed, utilizing MCF-7 human breast cancer cells, K562 human leukemia cells, and their 
corresponding drug resistance cell lines MCF-7/DNR, K562/DOX. As shown in Table 1, ADOX 
showed lower IC50 values against resistant cell lines MCF-7/DNR (3.5 μM) and K562/Dox (0.87 μM) 
cells than DOX (20 μM and 27 μM, respectively), whereas ADOX showed higher IC50 values against 
drug-sensitive cell lines MCF-7 (2.2 μM) and K562/Dox (0.64 μM) cells than DOX (0.11 μM and 
0.080 μM respectively). Therefore, drug resistance index values (DRI, ratio of IC50 in drug-resistant 
cells over IC50 in drug-sensitive cells) of ADOX were 1.6 and 1.4 μM, respectively, which were much 
smaller than those of DOX. The MTS assay results indicated that, unlike DOX, ADOX could Int. J. Mol. Sci. 2012, 13                 
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efficiently overcome drug resistance. Real-time PCR data indicated that the resistant cell lines 
MCF-7/DNR and K562/DOX were up-regulated in the expression of MDR1 (the gene product of 
MDR1 is P-gp), as compared with MCF-7 and K562 cell lines (Figure 3A,B). The P-gp protein was 
undetectable in drug-sensitive cell, while P-gp was significantly induced in drug-resistant cell as 
confirmed by Western blot [20]. This meant that ADOX might overcome drug resistance via avert the 
P-gp recognition. To prove this hypothesis, P-gp inhibitor cyclosporine A (CsA) was employed in the 
MTS assays (Figure 4) and FACS experiments (Figure 5). As expected, the addition of CsA to 
drug-resistant cell lines could enhance the intracellular concentration of ADOX (Figure 5A,B), and in 
turn lower the IC50 values (Figure 4). And the addition of CsA to drug-resistant cell lines had little 
effect on the retention and cytotoxicities of DOX, which strongly supported that modifications of sugar 
moiety of anthracycline drug DOX could well overcome P-gp mediated drug resistance. 
Table 1. The cytotoxicities (IC50 μM) of DOX and ADOX (MTS Assay). 
Cell lines and DRI 
a DOX  ADOX 
MCF-7 cell line  0.11 2.2 
MCF-7/DNR cell line 
b 20  3.5 
DRI
a 182  1.6 
K562 cell line  0.080  0.64 
K562/DOX cell line 
b 27  0.87 
DRI 
a 338  1.4 
CV-1 cell line 
c 25  2.8 
1.5 μM-CPT-CV-1 cell line
d >  10  6.6 
4 μM-CPT-CV-1 cell line
d >  10  2.6 
3 μM-mAMSA-CV-1 cell line 
d >  10  2.4 
a DRI is the abbreviation for drug resistant index, which is equal to the ratio of IC50 in 
drug-resistant cells (MCF-7/DNR and K562/DOX) over IC50 in drug-sensitive cells (breast cancer 
MCF-7 cells and leukemia K562 cells); 
b Drug resistant cell lines; 
c CV-1 is African green monkey 
kidney cell line; 
d 1.5 μM CPT-CV-1, 4 μM CPT-CV-1 and 3 μM mAMSA-CV-1 were drug 
resistant cell lines that were selected stepwise for camptothecin or mAMSA resistance. They were 
finally maintained in 1.5 μM camptothecin, 4 μM camptothecin and 3 μM mAMSA, respectively. 
Figure 3. Real-time PCR results of MDR1 mRNA levels. (A) Breast cancer cell lines 
MCF-7 and drug-resistant cell lines MCF-7/DNR; (B) Leukemia cell lines K562 and 
drug-resistant cell lines K562/DOX. Compared with the MDR1 mRNA levels in 
drug-sensitive cells, that in drug resistant cells were significant higher (** P < 0.01). 
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Figure 4. Cytotoxicities of DOX and ADOX in the presence (w/o 5 μM CsA) or absence 
(w/5 μM CsA) of 5 μM cyclosporine A (CsA) on drug-resistant breast cancer MCF-7/DNR 
(3.5 μM) and leukemia K562/DOX (1.0 μM) cell lines. This figure is an analysis of the 
IC50 data in table 1. The “control” refers to the absence of DOX/ADOX, CsA alone (5 μM) 
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Figure 5. Drug uptake and efflux of DOX and ADOX (2 μM) in drug-resistant leukemia 
cells (K562/DOX) in the presence (green line) or the absence (black line) of P-gp inhibitor 
(5 μM CsA) by FACS. Red filled area is control (cell without drug treatment). Black is cell 
with drug treatment, but without CsA. Green is cell with drug treatment, with CsA. 
 Int. J. Mol. Sci. 2012, 13                 
 
3678
To explore the potential of ADOX in clinical applications, in vivo efficacy and toxicity experiments 
were performed. In the xenograft mouse model experiments, 10
7 drug-resistant leukemia K562/DOX 
cells were injected subcutaneously into nude mice. After 14 days, the tumor reached greater than  
100 mm
3. From day 15, ADOX (5 or 10 mg/kg) and DOX (5 or 10 mg/kg) were injected in to the mice 
intraperitoneally twice per week for 3 weeks. The tumor volume was measured every 3 days. As 
shown in Figure 6, On 15, 18, 21, 24, 27, 30, 33 and 36 days, the average tumor sizes of control group 
were respectively 158.27, 382.92, 759.99, 1116.13, 1626.12, 2712.98, 3503.27, 4101.17 and 4219.97 mm
3, 
while that of DOX group were respectively 158.11, 242.37, 449.16, 678.09, 1097.01, 1433.07, 2031.04 
and 2763.80 mm
3, and that of ADOX group were respectively 141.66, 173.87, 284.57, 417.58, 678.10, 
859.14, 1276.01, 1652.39 and 2172.12 mm
3. Tumor growth was very rapid in the control group 
(without drug treatment), whereas ADOX and DOX significantly inhibited tumor growth after drug 
administration. ADOX (5 mg/kg) showed 1.9-fold higher maximum growth inhibition rate against 
drug-resistant K562/DOX than DOX (Figure 6A), indicating that in vivo efficacy of ADOX was 
superior to that of DOX.   
When ADOX and DOX were given to the xenograft model at the dose of 10 mg/kg twice a week 
for 3 weeks, the body weight of DOX-treated mice decreased about 18% and all of them died after 
three-week-administration, while the ADOX treatment group and control group did not show any 
significant body weight change (Figure 6B). All animals (8/8) in the ADOX group survived (100%) 
after 50 days, while the mice in the DOX group (6/6) died before 30 days (due to both tumor growth 
and drug toxicity; 50% of the mice died before 20 days). The mice in the control group (5/5) all died in 
33 days (50% of the mice died in 25 days) (Figure 6C). To further test the in vivo toxicities of ADOX, 
mice LD50 tests were performed, in which the mice were divided into six groups. The doses of ADOX 
in the six groups ranged from 120 mg/kg to 20 mg/kg, and the dose ratio of adjacent group was 0.7. 
After one dose i.p. administration of ADOX, the mice were observed for 14 days. The LD50 of ADOX 
in mice was calculated to be 35 mg/kg (Table 2), which was more than two folds of the reported LD50 
value of DOX (14 mg/kg) [21]. All these experiments indicated that in vivo administration of ADOX 
could induce less toxicity than DOX. 
Table 2. Mouse LD50 test of ADOX. 
Dose (mg/kg) 
a  120  84 59 41 29 20 
Number of mice in test 
b 10 
c  10 10 10 10 10 
Number  of  dead  mice  9 7 6 6 4 0 
a LD50 value of ADOX was 35 mg/kg, which was determined by using software Origin 7.5; 
b The 
mice were observed for fourteen days after one-dose-administration of ADOX, ip; 
c There were five 
male and five female Balb/c mice in each group, and they weighed between 18–22 gram. Int. J. Mol. Sci. 2012, 13                 
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Figure 6. In vivo anticancer activity and cytotoxicity of DOX and ADOX in xenograft 
mice model of drug-resistant leukemia cells (K562/DOX). (A) Anticancer activity;  
(B) Relative body weight change; (C) Animal survival rate. N = 8 for each group. Each 
point represents the mean ± SE of each group. 
 
3. Experimental Section 
3.1. Synthesis 
All solvents were dried with a solvent-purification system (Innovative Technology, Inc.). DNR 
hydrochloride (Greenfield Chemicals, Inc.) and DOX hydrochloride (Hisun Pharma) were directly 
used without further purification. Analytical TLC was carried out on E. Merck silica gel 60 F254 
aluminum-backed plates. The 230–400 mesh size silica gel (EMD Chemicals, Inc.) was utilized for all 
chromatographic purifications. All other reagents were purchased from Aldrich, and were used without 
further purification. 
1H and 
13C NMR spectra and the high-resolution mass spectra were collected at 
The Ohio State University Campus Chemical instrumentation Center. Elemental analysis was carried 
out on a Heraeus VarioEL-III C, H, N analyzer. The purity of the title compound ADOX was 
determined > 96% by HPLC analysis (Agilent 1200 HPLC (XDB-C18 column, 5 µm, 4.6 × 150 mm), 
Conditions: 0.6 mL/min, CH3CN/H2O (1:1), λ = 254 nm, tR = 8.8 min). Int. J. Mol. Sci. 2012, 13                 
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3.1.1. Glycosylation for Preparation of 1′,14-O-Diacetyl-3′-azido-DOX(7) (Scheme 1) 
Doxorubicinone-14-acetate 6 (1 mmol), molecular sieves 4 Å (800 mg), NIS (1.2 mmol), and 3  
(1.2 mmol) was dissolved in CH2Cl2 and stirred for 1 h at rt. A solution of TfOH (0.1 mmol) in CH2Cl2 
was added and stirred at 0 °C for 30 min. The reaction mixture was diluted with CH2Cl2 (50 mL), 
washed with aqueous Na2S2O3 (50 mL), brine (50 mL), dried (Na2SO4) and concentrated, the crude 
product was purified by column chromatography to afford compound 7 as a red solid (64%). 
1H NMR 
(400 MHz, CDCl3) δ13.92 (1H, s, HO-6), 13.34 (1H, s, HO-11), 8.03 (1H, d, J = 7.6 Hz, H-1), 7.78 
(1H, t, J = 8.0 Hz, H-2), 7.37 (1H, d, J = 8.8 Hz, H-3), 5.30 (1H, d, J = 2.4 Hz, H-1′), 5.20 (2H, m, 
Ha-14, Ha-10,), 4.96 (1H, m, Hb-14), 4.85 (1H, t, J = 6.4 Hz, Ha-8), 4.09 (3H, s, MeO-4), 4.05 (1H, m, 
Hb-10), 3.92 (2H, m, H-7, H-5′), 2.73 (2H, m, Hb-8, H-4′), 2.24 (2H, m, Ha-2′, H-3′), 2.20 (3H, s, 
AcO), 2.17 (3H, s, AcO), 2.06 (1H, m, Hb-2′), 1.09 (3H, d, J = 6.4 Hz, H-6′). 
13C NMR (100 MHz, 
CDCl3) δ200.7, 186.9, 186.6, 170.5, 160.9, 156.5, 155.1, 135.6, 135.5, 133.9, 120.9, 119.7, 118.3, 
111.4, 111.3, 94.0, 80.6, 70.3, 70.0, 65.9, 64.6, 58.0, 56.6, 54.2, 36.6, 30.4, 29.5, 20.7, 20.4, 16.5. MS 
ES
+ m/z 692 [M + K]
+. Anal. calcd for C31H31N3O13: C, 56.97; H, 4.78; N, 6.43. Found: C, 56.91;  
H, 4.86; N, 6.36. 
3.1.2. Deprotection of 7 to Title Compound ADOX (Scheme 1) 
A solution of DOX analogue 7 (100 mg) in THF (5 mL) was cooled in ice-bath to 0 °C, and then 
0.1 M NaOH aqueous solution (70 mL) which was cooled in advance in ice-bath was added. After 
stirring for 8 h, the reaction mixture was neutralized with 0.1 M citric acid, and extracted with CHCl3. 
The extractions were washed with saturated aqueous NaHCO3 solution. Concentration and 
chromatographic purification on silica gel column (MeOH/CH2Cl2 1:100–1:70) provided the product 
ADOX in yield of 70%. 
1H NMR (400 MHz, CDCl3) δ 13.91 (1H, s, HO-6), 13.14 (1H, s, HO-11), 
7.94 (1H, dd, J = 7.6 Hz, H-1), 7.69 (1H, t, J = 8.0 Hz, H-2), 7.30 (1H, d, J = 8.0 Hz, H-3), 5.49 (1H, d, 
J = 4.0 Hz, H-1′), 5.22 (1H, m, H-7), 4.65 (2H, s, H-14), 4.41 (1H, s, HO-9), 3.99 (3H, s, MeO-4), 3.94 
(1H, m, H-5′), 3.63 (1H, s, H-4′), 3.49 (1H, m, H-3′), 3.19 (1H, dd, J = 1.6 Hz, J = 18.8 Hz, Ha-10), 
2.93 (1H, d, J = 18.8 Hz, Hb-10), 2.25 (1H, m, Ha-8), 2.04 (2H, m, Hb-8, Ha-2′), 1.82 (1H, m, Hb-2′), 
1.24 (3H, d, J = 6.4 Hz, H-6′). 
13C NMR (100 MHz, CDCl3)  213.1, 186.8, 186.5, 160.9, 155.8, 155.3, 
135.5, 135.2, 133.1, 133.0, 120.7, 119.6, 118.3, 111.4, 111.3, 100.3, 69.5, 69.1, 66.9, 65.1, 56.4, 35.2, 
33.7, 28.1, 16.5. MS ES
+ m/z 592 [M + Na]
+. Anal. calcd for C27H27N3O11: C, 56.94; H, 4.78; N, 7.38. 
Found: C, 56.90; H, 4.88; N, 7.30. 
3.2. Biology 
3.2.1. Cell Culture 
Drug-sensitive leukemia cells K562, breast cancer cells MCF-7 and drug-resistant leukemia cells 
K562/DOX, breast cancer cells MCF-7/DNR were gifts from J. P. Marie (Institute National de la Sante 
et de la Recherche Medicale, E9912, University of Paris 6, Paris, France). The cells (2,000–10,000) 
were cultured in RPMI 1640 supplemented with 10% fetal bovine serum (FBS),   
1% non-essential amino acid and Penicillin (100 units/mL)/Streptomycin (100 μg/mL) in a humidified 
atmosphere of 5% CO2 and 95% air at 37 °C. Culture medium was changed every 2 to 3 days. Before Int. J. Mol. Sci. 2012, 13                 
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each experiment, K562/DOX cells were stimulated with 0.1 μM DOX at least for one week and then 
cultured for 10 days without DOX stimulation. It was assured that P-gp expression level was similar in 
every experiment. 
3.2.2. MTS Assay of ADOX 
Drug-sensitive and drug-resistant cells (2,000–10,000) were seeded in 96 well plates in RPMI-1640 
and incubated for 24 h. The exponentially growing cancer cells were incubated with various 
concentrations of compounds for 72 h at 37 °C (5% CO2, 95% humidity). After 72 h incubation, 
tetrazolium[3-(4,5-dimethythiazol-2-yl)]-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, 
inner salt (MTS, final concentration, 2 mg/mL) and phenazine methosulfate (PMS, final concentration 
25 μM) were mixed and added directly to the cells. After incubated for 3 h at 37 °C, the absorbance of 
formazan (the metabolite of MTS by viable cells) was measured at 490 nm. The IC50 values of the 
compounds for cytotoxicity were calculated by WinNonlin software [22] from the dose-response 
curves. 
3.2.3. RNA Extraction and Real-Time PCR Analysis 
RNA was extracted from cells using Trizol reagent (Invitrogen, Carlsbad, CA, USA) according to 
the manufacturer’s instructions. Real-time PCR was performed using SYBR Green as the dye. The 
MDR1 mRNA expression level in each cell line is calculated against β-actin as a control. The MDR1 
level in K562/DOX was calculated using K562 as control. 
3.2.4. Flow Cytometry (FACS) 
The assay was performed on a Becton-Dickinson FACS caliber (San Jose, CA, USA) equipped with 
an ultraviolet argon laser (excitation at 488 nm, emission at 530/30 and 570/30 nm band-pass filters). 
Analysis was stopped on acquisition of 50,000 cells. Log fluorescence was collected and displayed as 
single parameter histograms. Cell media was replaced with fresh 10% FBS RMPI 1640 containing no 
P-gp inhibitor Cyclosporine (CsA), 60 min before experiment. The cells were centrifuged (1000 rpm 
for 3 min) at room temperature and resuspended in 10% FBS RMPI1640. 10 million cells (in 50 μL) 
were transferred to plastic tubes containing 1.95 mL of incubation media with DOX or ADOX. In the 
uptake phase, cells were incubated with 2 μM DOX or ADOX in 10% FBS RMPI1640 in the presence 
or absence of 5 μM CsA for 30 min at 37 °C. After centrifugation (1000 rpm for 3 min at 4 °C), the 
cells were separated into equally two tubes. One tube was washed once with ice cold RMPI (no FBS) 
and transferred to FACS tube in the staining buffer on ice. These cells represent drug uptake phase. 
The other tubes were reincubated in 10% FBS RMPI1640 in the presence or absence of 5 μM CsA for 
an additional 30 min at 37 °C. This represents the drug efflux phase. After final centrifugation  
(1000 rpm for 3 min at 4 °C), the supernatant was removed. The cells were washed once with cold 
RMPI 1640, and the cell suspension in staining was transferred to FACS tubes. The drug accumulation 
in the cells was analyzed by FACS. Int. J. Mol. Sci. 2012, 13                 
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3.2.5. Anticancer Activity of ADOX Against Drug-Resistant Cancers in Xenograft Model 
Female, 5-7-week-old athymic nu/nu mice were purchased from the Charles River laboratories. 
Cells (1 × 10
7) were injected subcutaneously into the right flanks of the mice. Mice bearing tumors of 
100–300 mm
3 in volume (usually 10–15 days after tumor inoculation) were randomized into eight 
mice per group. Mice were treated with: (1) vehicle alone; (2) DOX at 5 or 10 mg/kg, i.p. twice per 
week for six injections; or (3) ADOX at 5 or 10 mg/kg, i.p. twice per week for six injections. Tumor 
volume (V) was recorded every 3 days as V = 0.5 l w
2, where l and w are the longest and shortest 
diameters of the tumor mass (in mm), respectively. Body weight was also recorded every 3 days to 
monitor the toxicity of the treatment. The statistical significance was analyzed using Student’s t test, 
and the differences were considered significant at P < 0.05. 
3.2.6. Acute Toxicity of ADOX Determined by Mouse LD50 Test 
Balb/c mice (half male and half female, weighing between 18–22 gram), were obtained from Center 
for New Drug Evaluation in Shandong University, China. Mice were randomly divided into 6 groups, 
and the corresponding dose levels were 120, 84, 59, 41, 29 and 20 mg/kg respectively. There were five 
male and five female mice in each group. The mice were observed for 14 days after 
one-dose-administration of ADOX, i.p. Numbers of dead mice in each group were recorded (Table 2), 
and LD50 value was determined by using software Origin 7.5 [23]. 
3.3. Computation 
3.3.1. Molecular Docking of DOX and ADOX to P-gp 
The crystal structure of P-gp (PDB entry:3G60) was chosen for molecular docking. Polar hydrogen 
atoms were added, and Kollman-all charges were assigned. Hydrogen atoms were added to the 3D 
ligand structures and all atoms were assigned with AM1-BCC partial charges. The position and 
conformation of each compound were optimized first by the anchor fragment orientation and then by 
the torsion minimization method implemented in the DOCK 6 program [24]. Fifty conformations and a 
maximum of 100 anchor orientations for each compound were generated, and all of the docked 
conformations were energy minimized by 100 iterations following procedures as described in literature. 
The docked molecules were ranked based on the sum of the van der Waals and electrostatic energies 
implemented in the DOCK 6 program. 
3.3.2. Statistics 
All values are expressed as means ± SD. When appropriate, statistical significance (defined as  
P < 0.05) was determined by Student’s t test. 
4. Conclusions 
In this study, a new DOX derivative, ADOX, was synthesized which bore an azido group at the C-3 
position of the sugar moiety. ADOX could be conveniently prepared from DOX via one pot diazo 
transfer reaction in moderate yield as described previously [10]. In this study, ADOX was prepared Int. J. Mol. Sci. 2012, 13                 
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from DNR which was much cheaper than DOX. ADOX exhibited potent anticancer activity both in 
drug-sensitive tumor cells (MCF-7 and K562), and in drug-resistant cells (MCF-7/DNR and 
K562/DOX). Although ADOX proved less effective in drug-sensitive K562 cells than DOX, it was 
much more effective than DOX in drug-resistant cells, which was helpful to overcome the 
disadvantage of MDR. Its DRI values were less than 2, which were over 100-fold lower than those of 
DOX. Considering the dramatic high level of MDR1 mRNA levels in these two drug resistant cell 
lines, we hypothesized the small DRI values of ADOX were attributed to its abolishment of P-gp 
recognition. This was supported by the MTS experiments and FACS experiments with the addition of 
P-gp inhibitor CsA. The molecular modeling using 3G60, a mouse homolog to human P-gp [12], were 
performed to prove that ADOX was a much weaker binding substrate to P-gp than DOX. The 
computational binding free energy of ADOX to P-gp was 1.31 kcal/mol, higher than that of DOX 
(−12.70 kcal/mol). 
In vivo efficacy and toxicity tests were carried out. Compared with DOX, ADOX was more 
effective in shrinking tumor volume size in drug-resistant K562/DOX xenograft mice model 
experiments via consecutive i.p. administration of 5 mg/kg dose every three days. At the same time, 
ADOX was less toxic than DOX. The mice LD50 value of ADOX was determined to be 35 mg/kg, 
approximately double the reported data of DOX (14 mg/kg) [21]. The current in vivo assay results 
proved ADOX as a promising drug candidate, and warranted it for further pre-clinical evaluations. 
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